aditya birla sun life flexi cap fund  - AI Investments Steady Growth
aditya birla sun life flexi cap fund  - AI Investments Steady Growth
aditya birla sun life flexi cap fund  - AI Investments Steady Growth
aditya birla sun life flexi cap fund  - AI Investments Steady Growth
aditya birla sun life flexi cap fund  - AI Investments Steady Growth
aditya birla sun life flexi cap fund  - AI Investments Steady Growth
aditya birla sun life flexi cap fund  - AI Investments Steady Growth
aditya birla sun life flexi cap fund  - AI Investments Steady Growth

aditya birla sun life flexi cap fund - AI Investments Steady Growth

₹1205

aditya birla sun life flexi cap fund ✌️【365vc.net】✌️Invest smartly in blockchain technology. Start small, earn big—₹500 to 100% returns monthly.

quantity
Add to Wishlist
Product Description

aditya birla sun life flexi cap fund ✌️【365vc.net】✌️Invest smartly in blockchain technology. Start small, earn big—₹500 to 100% returns monthly.

aditya birla sun life flexi cap fund ✌️【365vc.net】✌️Invest smartly in blockchain technology. Start small, earn big—₹500 to 100% returns monthly.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

aditya birla sun life flexi cap fund ✌️【365vc.net】✌️Invest with confidence using AI insights. Start at ₹500 and watch your wealth grow exponentially.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

aditya birla sun life flexi cap fund ✌️【365vc.net】✌️Small investment, big returns! Start at ₹500 and grow your wealth month by month.The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

aditya birla sun life flexi cap fund ✌️【365vc.net】✌️Save, invest, and grow! ₹500 to begin, with potential for 100% monthly profits.The underperformance persists despite a 22.aditya birla sun life flexi cap fund Stock Market Investments: Low Risk, High Rewards

Related Products